Search

Displaying results 1541 - 1550 of 10000 in total
  1. Drug

    Terazosin

    go.drugbank.com/drugs/DB01162
    ApprovedInvestigational

    Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate[A176837].

    Mixtures: Hytrin-7 Tabs 1mg-7 Tabs 2mg-14 Tabs 5mg, Hytrin-7 Tabs 1mg-7 Tabs 2mg-14 Tabs 5mgCategories: Drugs Used in Benign Prostatic Hypertrophy
  2. Drug

    Water

    go.drugbank.com/drugs/DB09145
    ApprovedInvestigational

    Water is a liquid at standard ambient temperature and pressure, but it often co-exists on Earth with its solid state, ice; and gaseous state, steam (water vapor).

    Mixtures: ORAZOLE ® 10 MG CAPSULA, Monoclate-P - 200-350iu/vialProducts: Fendall 2000 Pure Flow, N/A
  3. Drug

    Miglustat

    go.drugbank.com/drugs/DB00419
    ApprovedInvestigational

    Miglustat was first developed as an anti-HIV agent in the 1990s. … It has recently been approved for treatment of progressive neurological symptoms in adult and pediatric patients in the European Union, Brazil, and South Korea.

    Synonyms: 1,5-(butylimino)-1,5-dideoxy, D-glucitol, N-(n-Butyl)deoxynojirimycinProducts: ZAVESCA® 100 MG, Miglustat G.L. 100 mg-Hartkapseln
  4. Drug

    Manganese gluconate

    go.drugbank.com/drugs/DB11141
    Approved

    Manganese gluconate is a direct ingredient in food substances as a nutrient supplement. In pharmaceutical preparations it is used as a [DB06757] supplement. … It is typically obtained by reacting manganese carbonate with gluconic acid in aqueous medium and then crystallizing the product to form a slightly pink powder.

    Mixtures: Vitamin E 400 Iu With Selenium, Vitamin C & Manganese, Cal-mag Plus K, Mn and Zn CapletsSynonyms: Manganese D-gluconate
  5. Drug

    Eliglustat

    go.drugbank.com/drugs/DB09039
    ApprovedInvestigational

    [L41404,A7634] Eliglustat was approved by the FDA in August 2014 as an oral substrate reduction therapy for the first-line treatment of type 1 Gaucher disease. … [A3752,L41404] Gaucher disease is a rare genetic disorder characterized by the deficiency of acid β-glucosidase, an enzyme that converts glucosylceramide into glucose and ceramide.

    Synonyms: N-[(1R,2R)-1-(2,3-Dihydro-1,4-benzodioxin-6-yl)-1-hydroxy-3-(1-pyrrolidinyl)-2-propanyl]octanamideProducts: ELUXAT 84 MG SERT KAPSÜL, CERDELGA® 84 MG CÁPSULA DURA
  6. Drug

    Sebelipase alfa

    go.drugbank.com/drugs/DB11563
    ApprovedInvestigational

    This lipid accumulation can lead to end-organ damage in the form of liver dysfunction or malabsorption secondary to intestinal dysfunction. … The lysosomal acid lipase (LAL) enzyme is found in lysosomes and is primarily responsible for the metabolism of lipids, and its absence or deficiency results in the accumulation of lipids in various organs

    Products: KANUMA® 2 MG/ML CONCENTRADO PARA SOLUCION PARA INFUSION.
  7. Drug

    Icosapent ethyl

    go.drugbank.com/drugs/DB08887
    ApprovedInvestigationalNutraceutical

    It is used as an adjunct therapy for severe hypertriglyceridemia (TG levels > 500 mg/dL) and to reduce the risk of cardiovascular events in certain patients with elevated triglycerides. … FDA approved on July 26, 2012.

    Synonyms: E-EPA
  8. Drug

    Tigecycline

    go.drugbank.com/drugs/DB00560
    ApprovedInvestigational

    Food and Drug Administration (FDA) on June 17, 2005. … It was developed in response to the growing prevalence of antibiotic resistance in bacteria such as Staphylococcus aureus. It was granted fast-track approval by the U.S.

    Products: TIGLEX 50 MG, TIGECLIN® 50 MG VIAL
  9. Drug

    Metandienone

    go.drugbank.com/drugs/DB13586
    ApprovedWithdrawn

    Metandienone is an orally active anabolic androgenic steroid. It was introduced to the market in the 1960s but later discontinued and withdrawn from the market. … Although it is prohibited in and outside competition by the World Anti-Doping Agency, metandienone continues to be marketed and misused as a performance-enhancing drug in sports.

    Products: เมตาโบลอน 20, METABOLON 20
  10. Drug

    Olaparib

    go.drugbank.com/drugs/DB09074
    ApprovedInvestigational

    [L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014,[A246020] and by Health Canada in April 2016.[L42820] … [L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell

    Products: LYNPARZA® 100 MG, LYNPARZA (100 MG TABLET)